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Abstract
 
 
Cancer research is continuously shedding light into these worldwide leading diseases. It 
is mandatory to have higher knowledge in cancer biology to consequently find out new 
candidate biomarkers and therapeutics. Among all of them, Colorectal cancer is the most 
commonly seen of human malignant cancers and has the third highest mortality rate
[1]
. Since 
the release of the first human genome sequence in 2004, new techniques have 
revolutionised the study of genetics and its possible applications. A broad type of 
studies has been carried out; being Single Nucleotide Polymorphisms and Copy Number 
Variants the most intensively studied analysis. However, other kinds of mutations 
involving larger parts of the genome, the so-called structural variants, have been 
substantially less analyzed due to technical limitations. High-throughput sequencing 
methods seem to have lowered these restrictions. 
 
In this study, gene fusions have been searched in whole exome sequencing samples 
taking 42 paired normal and cancer tissues. Beginning with short-read files obtained 
with the mentioned method, they have been aligned against a reference genome to later 
be analyzed with Breakdancer, a structural variant calling algorithm. After some 
filtering criteria performed in order to remove a high proportion of false positives, a 
highly probable list of 22 balanced structural variants (translocations and/or inversions) 
has been manually studied to get a final result of 20 chromosomal rearrangements, 8 of 
which are considered gene fusions. In addition, it has been found that one recurrent 
translocation seen in recent studies is indeed a false positive. Further studies taking into 
account these results may contribute to the findings of new biomarkers for certain 
subtypes of colorectal cancer. 
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1. Introduction 
 
Advances in high-throughput sequencing during the last years have enabled the 
potential to identify almost all kinds of variations in any genomic region
[2]
, from single 
nucleotide polymorphisms (SNPs) to large structural variants (SVs). 
 
Structural variants can impact on the genome variation and therefore, it is important to 
consider them in cancer genetics
[3]
. Structural variants can be classified as germline 
(being most of them benign) and somatic
[4]
. In many cancer genomes, recurrent 
chromosomal rearrangements in specific types of cancer have been detected, such as 
BCR-ABL fusion gene from a resulting translocation between chromosomes 9 and 22 
found in a high proportion of Chronic Myelogenous Leukaemia patients. 
 
Due to the genome changes driven by structural variants (formation of fusion genes, 
changes in regulatory elements or changes in copy number) significant differences in 
both overexpression of oncogenes and underexpression of tumor suppressor genes may 
take place
 [5]
. Therefore, detecting correctly all kinds of variations in a specific cancer 
genome could help in the understanding of the disease biology. In addition, it could 
allow designing new personalized therapies as well as identifying oncogenic-driving-
mutations that can be therapeutically targetable in the near future. 
 
Colorectal cancer accounts for 9.4% and 10.1% of all types of cancer in men and 
women, respectively. Is a major case of morbidity and mortality throughout the world 
although not uniformly spread. Western countries (Europe, United States, Canada, 
Australia and New Zealand) have higher incidence of colorectal cancer compared with 
African and Asian countries
[6]
. 
 
Like other types of malign tumours, the overall survival is dramatically dependent on 
the stage of the disease at diagnosis, ranging from 90% of 5-year survival rates for 
patients detected at an early stage at diagnosis, to 10% in patients detected at later 
stages
[7]
. For this reason it is extremely important to develop not only effective therapies 
but also high sensitivity biomarkers. 
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Few articles published recently have found several fusion genes in colorectal cancers, 
some of which are recurrent events, like NAV2-TCF7L1
[8]
 or TMP3-NTRK1
[9]
. 
However, it seems that chromosomal rearrangements are not very common in these 
diseases
[10]
, in contrast with haematological malignancies, where there have been found 
thousands of chromosomal rearrangements and hundreds of gene fusions. 
 
This study is an attempt to detect balanced chromosomal rearrangements (translocations 
and inversions) and especially, those that generate fusion genes in colon cancer DNA 
samples. Consequently, it can be a method to perform fusion gene detection from whole 
exome sequencing (WES) data for further studies. 
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2. Materials and methods 
 
In order to carry out this analysis, an important number of software and applications 
have been used. The major steps developed to obtain accurate results are represented in 
a flow diagram showed in Figure 2.1. 
 
 
Figure 2.1. Flow diagram of the pipeline followed in this study. 
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2.1. Patients and samples 
The study included a subset of 42 paired adjacent normal and tumor tissues (84 
samples) from a previously described set of 100 patients with colon cancer diagnosed at 
stage II (colonomics project –CLX-: www.colonomics.org; NCBI BioProject 
PRJNA188510). All patients were recruited at the Bellvitge University Hospital 
(Barcelona, Spain). Written informed consent was obtained from all patients and the 
Institution’s Ethics Committee approved the protocol. DNA was extracted using a 
standard phenol-chloroform protocol. To ensure that adjacent and tumor tissues were 
paired, dynamic arrays were used to genotype 13 SNPs in the 84 samples. All 42 
adjacent normal tissues correctly matched with their corresponding tumor. Tumor DNA 
from an additional series of 227 CRC patients from the same hospital was used for 
validation purposes. This extended series was not restricted regarding site, stage and 
microsatellite instability phenotype
[11]
. 
 
2.2. Quality control of samples 
CLX samples analyzed here, have been studied before
[11]
. For this reason, it has not 
been necessary to perform a quality control of the samples because it has been done 
previously. Anyway, fastQC
[12]
 software was used to confirm the adequate quality of 
the samples for the most relevant parameters. 
  
2.3. Alignment of samples 
After that, samples were locally aligned against human genome 19 build 37 
(hg19/GRCh37) using Bowtie2
[13]
, an ultra-fast read mapping software (able to soft-
clipping). 
Bowtie2 was set up with a very sensitive alignment because all SVs detection programs 
use discordant mapped reads if the input samples are paired-end reads. Therefore, the 
more sensitive the alignment is the more number of discordant mapped reads the 
software will have to work with. Also, the type of alignment chosen was a local one due 
to the fact that most of those programs need soft-clipped reads as input (local alignment 
generates soft-clipped reads). 
 
2.4. Manipulation of alignment files 
Using Samtools
[14]
 and Picardtools
[15]
 alignment files have been manipulated to allow 
SV detection softwares to perform further analysis. Sorted alignments by genomic 
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coordinates, transformation from human readable format (uncompressed) to binary 
alignment format (compressed) and indexation have been performed using Samtools. 
Also, it has been selected only the reads that were unmapped or discordantly mapped in 
fastq format for a specific study (see Materials and Methods section 2.4.1). Duplicated 
reads were tagged with Picardtools’ Markduplicates, whereas read group names and 
samples were added with Picardtools’ AddOrReplaceReadGroups. Read duplicates have 
been removed, and those contained in regions of interest have been extracted. 
 
2.5. Structural variant finders 
 
2.5.1. Gustaf analysis 
The first SV detection tool used for this analysis is called Gustaf (Generic mUlti-SpliT 
Aligner Finder)
[16]
. According to the authors, Gustaf is able to detect and classify all 
kinds of genomic rearrangements ≥ 30 bp with a sensitivity of 0.993 and positive 
predictive value of 0.946 in 100 bp paired-end read simulated studies. Gustaf takes 
unmapped and discordant mapped reads (generated with Samtools) as input and then it 
uses a local aligner called Stellar to detect partial alignments of a read. Finally, Gustaf 
generates an output table with relevant information (chromosome, position, orientation, 
type of SV, exact breakpoint and number of supporting reads) using the generated 
output by Stellar. 
 
2.5.2. FACTERA analysis 
FACTERA (Fusion And Chromosomal Translocation Enumeration and Recovery 
Algorithm) is the second SV detection tool used. It is a brand new software that is able 
to correctly detect and classify structural variants with base pair resolution in a wide 
range of lengths
[2]
. It was used in order to find SVs in paired-end exome-wide 
sequencing data. FACTERA gives as an output a set of files with all necessary 
information about the type of the detected SV (translocation, inversion or deletion), 
chromosome, position, strand, breakpoint, and depth of reads supporting these events. 
 
2.5.3. Breakdancer analysis 
Breakdancer
[17]
, a widely used SV finder, was the next software used. Breakdancer has 
the ability to perform pooled analysis in which all samples are grouped together to reach 
higher sensitivity. However, due to computational limitations, this option was only 
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performed to detect SVs within chromosomes. Breakdancer was run for each matched 
normal and tumor samples to detect SVs between chromosomes (inter-chromosomal 
translocations) and all results were put together for final filtering. Three quality control 
steps were done before running the software to account for the coefficient of variation 
(CV) for each read group, the percentage of inter-chromosomal read pairs, and to assess 
for the histograms of the insert size distribution of each sample.  
Breakdancer analysis is divided in two steps. Firstly, it performs a configuration file 
with statistics for each read group (those used for the quality control checks). Secondly, 
the main program uses these statistics to generate a list of putative SVs. Of note, 
Breakdancer does not find the exact breakpoints but theoretic ones, which can be 
located within the predicted boundaries with 95% confidence intervals equal to twice 
standard deviation insert size
[18]
. For this reason, it was necessary to check manually for 
the exact breakpoints. 
 
2.6. Filtering process 
As a filtering criterion, R
[19]
 has been used to get a high confidence list of SV. The 
filtering steps performed have been: removal of all SVs found at least once in any of the 
normal samples, removal of insertions and deletions (CNV), establishment of a cut-off 
of more than four reads supporting a given SV. Finally; as mentioned in a recent 
study
[18]
, it has been looked for overlapping regions of low complexity and high 
repetitive regions for each of the resulting candidates using Simple Repeat and 
RepeatMasker tracks at UCSC browser
[20]
, respectively. 
 
2.7. Gene annotation 
The list of annotated genes for regions overlapping ±10bp the predicted breakpoints was 
obtained with Bedtools
[21]
. 
 
2.8. SV visualization 
Alignment files of the samples containing any of the SVs candidates in the list were 
visualized with Integrative Genomics Viewer
[22]
 (IGV).  The regions of interest have 
been manually inspected to see the amount of concordant paired reads, the ratio between 
concordant read pairs and discordant read pairs supporting the given SV, and also, to 
find out the real breakpoints when possible.  
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2.9. Defining exact breakpoints 
A chimera genome of 4,000bp was generated with 2,000bp before breakpoint 1 and 
2,000bp after breakpoint 2 to finally obtain real sequences of the surrounding SVs 
regions in cases where the real breakpoint was checked. Resulting fasta files had been 
established as reference genomes. Each sample containing an SV had been aligned with 
its own set up reference genome. The process to generate the resulting alignments was 
the same described in Materials and Methods section 2.2, except for a global alignment 
method. 
 
2.10. Final validation results 
As a final step before validating a candidate SV, a blast
[23]
 search against a sequence of 
about 100bp surrounding each breakpoint was made to see whether these sequences 
were aligned in any other region of the genome, or in contrast, they were a real fusion 
gene. 
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3. Results 
 
3.1. Alignment of the samples 
All 84 CLX samples (42 of which are normal tissue samples) have been aligned with 
Bowtie2 with no warnings or error messages. All samples have showed an overall 
alignment rate higher than 97%. Somatic structural rearrangements are not expected to 
be found on normal tissue samples, thus they have been used to filter and remove false 
positives. 
 
3.2. Gustaf SV analysis 
After alignments have been generated and properly reads have been selected (see 
Materials and Methods section 2.4.1), Stellar have been run in order to find all local 
alignments between two sequences. After several attempts to successfully generate the 
desired data, the only results found came from a partial sample of 2,000 reads and it 
took about 12 hours. Given a pool of 84 samples with most of them of more than 100 
million reads, Gustaf has been rejected for such analysis. Stellar is, in this case, a 
software unable to work efficiently due to time restrictions and Gustaf is designed to 
work under Stellar output in paired-end read analysis. Gustaf could be an interesting 
software to look for limited regions of interest, but not to work with WES data. 
 
3.3. Factera SV analysis 
Two example sequences have been tested with FACTERA giving the expected results. 
Both are samples from non-small cell lung cancer (NSCLC) patients, harbouring known 
rearrangements involving ROS1 or ALK genes and confirmed by FISH
[2]
. HCC78 
carries a chromosomal translocation that creates a gene fusion between SLC34A2 
(chromosome 4) and ROS1 (chromosome 6). H3122 carries an inversion in 
chromosome 2 that produces an EML4-ALK gene fusion. 
However, when CLX samples have been run under FACTERA with all the 
specifications correctly checked, no gene fusion has been found. Several hypotheses 
could explain this fact: low coverage in samples, too short reads in samples for the 
algorithm to work properly, the algorithm is not appropriate to analyze these samples. 
Notably, FACTERA has only been used in one published article by now. 
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3.4. Breakdancer SV analysis 
Breakdancer first step has generated a configuration file from which three quality 
control checks have been done in order to know whether there are or not some bam 
formatting errors or flag issues. Firstly, the CV of the insert size for each library is 
computed and should be about 0.2-0.3. Secondly, it has been computed the percentage 
of interchromosomal reads, which normally should not be larger than 3%. However, 
when analyzing tumor samples, the chances to find interchromosomal translocations 
increase substantially. Therefore, this percentage could be larger than 3% without 
meaning issues with sequencing or library construction. Finally, histograms of insert 
size distribution for each library have also been created. Ideally, a normal distribution is 
expected. In contrast, a bimodal distribution is not expected. Supplementary Table 1 
shows the CV for each sample, which are in the expected range. Supplementary Table 2 
shows the interchromosomal read flags. Supplementary Figure 1 shows the histograms 
of insert size distribution for a subset of samples (all showed the same distribution 
shape).  
 
When Breakdancer has been used to analyze the two mentioned example sequences, the 
expected gene fusions plus several de novo putative SVs are found. After applying 
filtering criteria (see Materials and Methods Section 2.5), the list of theoretical SVs is 
reduced substantially (see Table 3.1). However, the expected gene fusions are not 
filtered. 
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 Table 3.1. Filtered putative list of SVs from example sequences H3122 and HCC78 
Chr1 Pos1 Chr2 Pos2 Type Size # Reads # Reads lib 
chr2 29,446,006 chr2 29,448,464 ITX -116 49 H3122|49 
chr2 29,448,459 chr2 42,526,790 INV -215 120 H3122|120 
chr2 80,816,295 chr2 80,816,537 ITX -112 9 H3122|9 
chr2 141,665,342 chr2 141,665,677 ITX -113 8 H3122|8 
chr2 212,248,055 chr2 212,248,768 ITX -112 9 H3122|9 
chr2 212,543,272 chr2 212,544,021 ITX -112 8 H3122|8 
chr2 212,566,607 chr2 212,566,865 ITX -112 8 H3122|8 
chr2 212,587,034 chr2 212,587,262 ITX -112 8 H3122|8 
chr4 25,666,650 chr6 117,657,990 CTX -215 166 HCC78|166 
c
hr4 
25,666,856 chr6 117,658,325 CTX -215 180 HCC78|180 
Note. Pos1/Pos2: estimated breakpoint position for breakpoints 1 and 2, respectively.         
# Reads: number of reads supporting each SV. # Reads lib: number of reads supporting 
each SV from given samples. ITX: Intrachromosomal translocation. INV: Inversion. CTX: 
Interchromosomal translocation. 
 
After analyzing the example sequences, all CLX samples have been run under the same 
procedure. Regarding the output, initially 195,416 intrachromosomal SVs and 1,822 
interchromosomal SVs are found by Breakdancer. After filtering SVs found in normal 
samples, the list of putative SVs dropped to 14,206 intrachromosomal and 547 
interchromosomal. When removing insertions and deletions (only found in 
intrachromosomal output), 1,637 ITX and INV were found. Finally, establishing a cut-
off larger than 5 supporting reads for a given SV, the final list of putative SV was 
dropped to 13 intrachromosomal and 9 interchromosomal SVs (see Table 3.2). None of 
these variants overlap with both RepeatMasker and Simple Repeat data from the UCSC 
browser. 
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 Table 3.2 Filtered putative list of SVs from Colonomics Samples. 
Note. Pos1/Pos2: estimated breakpoint position for breakpoints 1 and 2, respectively.         
# Reads: number of reads supporting each SV. # Reads lib: number of reads supporting 
each SV from given samples. ITX: Intrachromosomal translocation. INV: Inversion. CTX: 
Interchromosomal translocation. 
 
 
 
 
Chr1 Pos1 Chr2 Pos2 Type Size # Reads # Reads_lib 
chr1 158,437,081 chr1 158,462,926 INV 18795 14 M2052_T|14 
chr3 138,244,667 chr3 138,311,552 INV 66231 8 H2019_T|8 
chr6 43,013,359 chr6 43,084,604 INV 57329 31 P2078_T|31 
chr6 47,759,047 chr6 47,773,202 ITX 12984 7 J2037_T|7 
chr7 86,570,184 chr7 86,583,225 ITX 12099 8 P2009_T|8 
chr8 125,578,901 chr8 128,229,741 ITX 1588774 25 Q2040_T|25 
chr9 72,334,210 chr9 72,347,754 INV 13691 21 H2019_T|21 
chr16 30,674,685 chr16 49,701,174 ITX 9511246 6 N2036_T|6 
chr17 34,049,990 chr17 340,54,582 ITX 356 27 A2027_T|27 
chr18 12,253,638 chr18 71,890,011 ITX 59635220 30 R2002_T|30 
chr20 21,378,936 chr20 21,737,240 INV 239813 6 Z2084_T|6 
chr20 57,565,196 chr20 59,304,571 INV 1694335 39 L2020_T|39 
chrX 30,327,808 chrX 53,825,218 INV 6713456 21 
A2027_T|1 
E2023_T|20 
chr1 156,186,627 chr20 26,189,745 CTX -208 9 S2016_T|9 
chr11 85,195,079 chr17 33,478,203 CTX -213 11 
T2093_T|4 
D2079_T|5 
Q2040_T|2 
chr1 3,789,601 chr20 30,274,613 CTX -211 8 P2009_T|8 
chr15 45,814,571 chr16 28,099,399 CTX -211 23 B2035_T|23 
chr16 23,593,973 chr17 11,630,939 CTX -214 8 D2079_T|8 
chr17 46,654,141 chr20 41,955,507 CTX -223 6 E2023_T|6 
chr2 242,357,530 chr3 123,590,919 CTX -208 8 S2016_T|8 
chr3 138,248,358 chr13 78,768,008 CTX -220 8 H2019_T|8 
chr9 72,333,617 chr10 127,593,850 CTX -220 22 H2019_T|22 
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3.5. Gene annotation 
The annotated genes for the predicted breakpoints have been obtained with Bedtools 
(see Table 3.3). Of note, nine of these positions are located in intergene regions. Three 
of these nine breakpoints have supporting reads lying within exon boundaries. This can 
happen if those reads are located close to the end of an exon. In such case, it could not 
be possible to construct the whole gene fusion sequence. For the other six predicted 
breakpoints, two possibilities could explain this fact. On the one hand, a given SV has 
aroused between a gene exon and any other region of the genome (i.e. intron, non-
coding region). On the other hand, if the two breakpoints of a certain SV are located out 
of exon boundaries, it could be a false positive result due to a mistake in the alignment 
method. 
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 Table 3.3. Genes overlapping breakpoint positions 
Chromosome Breakpoint Gene Symbol 
chr1 3,789,601 DFFB 
chr1 156,186,627 PMF1-BGLAP 
chr1 158,437,081 OR10K1 
chr1 158,462,926 AK057554 
chr2 242,357,530 FARP2 
chr3 123,590,919 MYLK 
chr3 138,244,667 
CEP70 chr3 138,248,358 
chr3 138,311,552 
chr6 43,013,359 CUL7 
chr6 43,084,604 PTK7 
chr6 47,759,047 
OPN5 
chr6 47,773,202 
chr7 86,570,184 
KIAA1324L 
chr7 86,583,225 
chr8 125,578,901 MTSS1 
chr8 128,229,741 CCAT1 
chr9 72,333,617 
PTAR1 chr9 72,334,210 
chr9 72,347,754 
chr10 127,593,850 FANK1 
chr11 85,195,079 DLG2 
chr13 78,768,008 RNF219-AS1 
chr15 45,814,571 SLC30A4 
chr16 23,593,973 NDUFAB1 
chr16 28,099,399 XPO6* 
chr16 30,674,685 FBRS 
chr16 49,701,174 ZNF423 
chr17 11,630,939 DNAH9 
chr17 33,478,203 UNC45B 
c
hr17 
34,049,990 
AP2B1 
chr17 34,054,582 
chr17 46,654,141 HOXB3 
chr18 12,253,638 CIDEA 
chr18 71,890,011 CYB5A 
chr20 21,378,936 NKX2-4 
chr20 21,737,240 PAX1* 
chr20 26,189,745 LOC284801 
chr20 30,274,613 BCL2L1 
chr20 41,955,507 SCARNA15* 
chr20 57,565,196 NELFCD 
chr20 59,304,571 LOC284857* 
chrX 30,327,808 NR0B1 
chrX 53,825,218 HUWE1* 
 * intergenic regions. Gene symbols annotated are the nearest ones 
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3.6. Chimeric gene fusion construction 
It has been tried to construct a fusion between DLG2 and UNC45B genes, a predicted 
gene fusion found in three tumor samples, and another one between MTSS1 and 
CCAT1, this last one found in one tumor sample (see table 3.2). For this purpose, it has 
been necessary to correctly check with IGV for the exact breakpoints, which in such 
cases they have been set up at chr11:85,195,232 and chr17:33,478,275 for DLG2-
UNC45B and chr8:125,580,720 and chr8:128,229,159 for MTSS1-CCAT. 
A chimera genome of 4,000bp has been generated with 2,000bp from chromosome 11 
(chr11:85,193,982-85,195,232) and 2,000bp from chromosome 17 (33,477,025-
33,478,275). The resulting fasta file has been established as a reference genome to 
which the three samples containing the mentioned translocation have been aligned with. 
The same procedure has been done to generate another chimera genome for the 
candidate gene fusion between MTSS1 and CCAT1. 
 
3.7. Visualization of results  
Using IGV, it has been possible to visualize the fusion genes with reads aligning in both 
sides of the breakpoints and reads aligning throughout the breakpoint. DLG2-UNC45B 
gene fusion has some mismatches with the quimeric reference whereas MTSS1-CCAT1 
does not, as it is possible to see in Figures 3.1 and 3.2, respectively. Equivalent 
alignments are represented in Supplementary Figures 2 and 3 in Annex A2 for the other 
2 samples with the recurrent putative gene fusion.  
 
Figure 3.1. Discordant reads surrounding SV detected in sample D2079 aligned against 
DLG2-UNC45B gene fusion chimera construct. Mismatches are represented as colored 
vertical lines. 
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Figure 3.2. Reads surrounding SV detected in sample Q2040 aligned against MTSS1-CCAT1 
gene fusion chimera construct. In this case there are no mismatches. 
 
3.8. Final filtering of false positives 
A blast search against 100bp surrounding the breakpoint of each gene fusion has been 
performed. To correctly validate a putative gene fusion, it is expected to find partial 
alignments with only its two separate sequences. However, in the case of DLG2-
UNC45B gene fusion, some other matches have been found (see Appendice A3). In 
particular this query sequence aligns with a similarity of 100% against rRNA genes 
(found in chrUn_gl0000220). 
 
3.9. Final validation of results 
To validate the hypothesis that DLG2-UNC45B fusion could be a false positive, all 
reads from the quimeric alignment and all the reads from the two original sites on the 
alignment against hg19 have been extracted. All these reads (5988) have been now 
aligned against chrUn_gl0000220 with Bowtie2 (same procedure explained in Materials 
and Methods section 2.2, except for a global alignment instead of a local one).  
 
When visualized the region that matched with DLG2-UNC45B in the blast query with 
IGV, a high number of mapping reads with a perfect alignment of the sequences against 
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chrUn_gl0000220 have been seen, as showed in Figure 3.3. Supplementary Figure 4 
and 5 in Annex A2 show equivalent alignments for the other two samples. 
 
 
Figure 3.3. Reads surrounding SV detected in sample D2079 aligned against chrUn_gl0000220. 
In contrast with Figure 3.1, now there are no mismatches and the number of supporting reads is 
higher. 
 
After manually finding real breakpoints for those samples where exact breakpoints 
could be determined, it has been found a total of 8 fusion genes, 4 of which have a short 
sequence surrounding the breakpoint without being sequenced (none of them reported 
previously), 3 rearrangements affecting the same gene and 7 rearrangements between 
genes and intergenic regions. In table 3.4 it is summarized this information. 
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Table 3.4. Summary table of all exact breakpoints found in SV calling, fusion gene 
formation and samples where they have been identified. 
Sample Breakpoint 1 Breakpoint 2 Fusion Gene 
H2019 Chr3:138,248,076 Chr13:78,768,197 CEP70 – RNF219-AS1 
H2019 Chr9:72,333,392 Chr10:127,594,138 PTAR1 – FANK1 
J2037 Chr6:47,759,662 Chr6:47,772,955* OPN5 – OPN5 
P2009 Chr7:86,570,571 Chr7:86,583,017* KIAA1324L – KIAA1324L 
P2009 Chr1:3,789,651 Chr20:30,274,613* DFFB – BCL2L1 
Q2040 Chr8:125,580,720 Chr8:128,229,159 MTSS1 – CCAT1 
N2036 Chr16:30,678,029* Chr16:49,701,137 FBRS – ZNF423 
A2027 Chr17:34,050,541* Chr17:34,054,490 AP2B1 – AP2B1 
R2002 Chr18:71,889,951 Chr18:12,254,445 CIDEA – n.c.r   
B2035 Chr15:45,814,389 Chr16:28,099,588 SCL30A4 – n.c.r. 
S2016 Chr2 Chr3 FARP2 – MYLK 
M2052 Chr1 Chr1 OR10K1 – n.c.r 
D2079 Chr16 Chr17  NDUFAB1 – DNAH9 
H2019 Chr3 Chr3 CEP70 – CEP70 
H2019 Chr9 Chr9 PTAR1 – PTAR1 
P2078 Chr6 Chr6 CUL7 – PTK7 
Z2084 Chr20 Chr20 NKX2-4 – n.c.r 
L2020 Chr20 Chr20 NELFCD – n.c.r.  
E2023 ChrX ChrX NROB1 – n.c.r. 
E2023 Chr17 Chr20 HOXB3 – n.c.r. 
S2016 Chr1 Chr20 PMF1/BGLAP – LOC284801** 
D2079 / Q2040 
/T2093 
Chr11:85,195,232 Chr17:33,478,275 DLG2 – UNC45B** 
Note: In bold those fusion genes with exact known breakpoint. Unknown exact breakpoints 
represented only by chromosome number. * intronic positions. ** False positive fusion genes. 
 24 
 
4. Discussion 
 
There are evidences that gene fusion events are not enough to explain malignant 
transformation in haematological tumors. In contrast, it seems that certain gene fusions 
associated with certain types of sarcoma are enough to develop malignancy in mice. 
However, it is not yet known whether carcinomas have the same behavior than 
haematological disorders or sarcomas
[10]
. 
 
Depending on several aspects of the chimeric gene formation, two options are expected: 
a loss of functionality for one or both genes in a fusion due to high structural changes or 
a change in the activity in the second of the genes in a fusion because of the change in 
epigenetic regulation
[10]
. Consequently; this somatically-acquired mutations could 
partially explain the role of certain genes (those presents in fusions) in the onset and 
progression of colon cancer. 
 
From all SVs found with exact breakpoint positions, three of them have both 
breakpoints within the same gene (see Table 3.4). Thus, instead of being considered 
gene fusions, they are considered as genes which products will differ from original ones 
in a variable degree. Those are OPN5, AP2B1 and KIAA1324L, found in samples 
J2037, A2027, and P2009, respectively.  
 
OPN5, or neuropsin, is an opsin gene whose product is a member of G-protein-coupled 
receptor family, mainly expressed in neural tissues, eye and testes
[24]
. The modification 
seen in one tumoral sample from colonomics affects exon 3. Nevertheless, due to its 
lack of expression in colon, it seems that OPN5 variant found is not a good candidate to 
explain onset or progression of this particular cancer. 
 
In contrast, AP2B1 is moderately expressed in both colon and rectum. It is involved in 
protein transport and among its related pathways are signaling by fibroblast growth 
factor receptor (FGFR). The variant found in colonomics sample, however, is only 
affected in the last exon, so little changes in gene product should be expected. 
Interestingly, this variant approaches the end of the mentioned gene to the beginning of 
RASL10B, a RAS-like protein with GTPase activity that could change their expression 
pattern. 
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KIAA1324L, also known as EIG121L, is involved in epithelial differentiation in 
embryonic development
[25]
. In addition, it is expressed in colon and rectal tissues
[26]
 but 
it is not clear its function, so it is difficult to know whether this variant could make 
some effect in the disease. The variant found here, is composed by the first four exons, 
just as spliced variant found in testes. 
 
Regarding the other variants (proper gene fusions) there are several different scenarios.  
 
MTSS1-CCAT1 fusion is an interesting rearrangement due to some aspects. MTSS1 
(metastasis suppressor 1) has been found overexpressed in colorectal cancer and it is 
positively correlated with low 5-year survival rates
[27]
. CCAT1 (colon cancer associated 
transcript 1) is a non-protein coding gene implicated in the transcriptional regulation of 
MYC
[28]
 and its expression is upregulated in colorectal cancer tissues
[29]
. The fusion 
found here is under regulation of CCAT1, so it should be expected that MTSS1 would 
be then overexpressed, and hence, this fusion could become a biomarker for predicting 
bad prognosis in CRC patients. 
 
In the case of PTAR1-FANK1, the fusion occurs between the last exon of PTAR1 and 
the first intron of FANK1, but given the fact that they are head to head genes, this 
fusion is going to generate two different products. The first one will be PTAR1 joined 
to an unpredictable sequence composed by part of the first intron and the first exon of 
FANK1. PTAR1 has prenyltransferase activity, which is known to be needed for 
oncogenic proteins such as Ras
[30]
, so it is expected that this fusion will have this 
activity. Furthermore, it will be under regulation of PTAR1. The product of this fusion 
gene will be regulated by FANK1, which is a gene involved in apoptosis
[31]
, and will be 
composed by the first exon of FANK1 and part of the last exon of PTAR1 joined to 
FANK1 intron 1. Taken together, it seems that cells producing these variants will 
partially loss apoptotic properties. 
 
DFFB-BCL2L1 fusion involves two genes with apoptotic properties which are 
moderately expressed in colon and rectum tissues. BCL2L1 gene have both actions pro-
apoptotic and anti-apoptotic depending on the splice variant expressed
[32]
. Again, as in 
the case of PTAR1-FANK1, these are head to head genes, so the gene fusion will 
 26 
 
generate two gene products, each one with the first gene properly coded and the second 
one coded in the wrong direction, giving an unexpected protein product. 
 
CEP70-RNF219AS1 is a fusion which joints a centrosomal protein coding gene 
(CEP70), which has mitotic functions, with an antisense RNA gene. The fusion will 
modify CEP70 protein but it is difficult to predict its consequences. 
 
With regards to FBRS-ZNF423 fusion, again are involved head to head genes. FBRS 
codes for fibrosin, a limphokine that induces fibroblast proliferation
[33]
. On the other 
hand, ZNF423 is a zinc finger protein that works as a transcription factor
[34]
. The 
products of this fusion will be partially translated genes linked with an unknown 
sequence. 
 
Regarding the other fusion genes, those where getting the exact breakpoint was not 
possible, 3 different fusion genes have been found, all of them between head to head 
genes. Therefore, the gene products in all cases will be part of one gene properly coded 
and part of another one coded in the wrong direction, with unknown result. 
 
FARP2-MYLK is composed of a gene related with Ras signaling pathway and involved 
in cytoskeleton modelling (FARP2)
[35]
 and MYLK, which codes for the light chain 
kinase of  myosin
[36]
. 
 
CUL7-PTK7 is a fusion gene which will code for both a component of an ubiquitin-
protein ligase complex
[37]
 and an inactive tyrosine kinase
[38]
. 
 
In contrast to the last fusions, NDUFAB1-DNAH9 will have only one gene product 
because DNAH9 is not expressed in colon tissue. Thus, the gene product will joint an 
unknown sequence from DNAH9 with the first 3 out of 4 exons of NDUFAB1, which 
product is a subcomplex of NADH dehydrogenase ubiquinone 1
[39]
. 
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5. Limitations 
 
This study has few limitations. Firstly, due to the amount of DNA needed to perform 
this sequencing technologies and the fact that cancer tissues are a combination of cells 
with different number of mutations, the sequencing of the whole exome is in fact the 
sequence of a mixture of DNA from different cells. This could decrease the power of 
detection of somatic structural rearrangements. 
 
Secondly, Breakdancer output has a tendency to generate a large list of false positives 
SVs due to the nature of the genome, where there are sites of low complexity or high 
repetitivity. For this reason, it is necessary to perform several non-standardized filtering 
steps where it is possible to remove some true positive values. In addition, breakpoints 
generated by Breakdancer are not real but approximated, which makes not viable any 
automatic analysis from this point on. With regards of the amount of supporting reads 
for a particular SV, it tends to give a lower value than what it is expected because all 
reads surrounding a real breakpoint plus their paired reads are not considered SVs 
supporting reads by this algorithm. In Figure 5.1 is shown an example of this. 
 
 
Figure 5.1: Alignment of reads from sample A2027T in 3’UTR of AP2B1 gene in chr17.q12. 
Green reads are considered discordant whereas grey reads are not. Rainbow sites are 
mismatches indicating the exact breakpoint of this SV. Breakdancer does not consider paired 
reads in grey as supporting reads for this SV because they are located in a proper distance 
between them. However, it has been demonstrated that rainbow-coloured part in rightmost grey 
read is in fact part of an ITX. Therefore, these pair of reads should be considered as supporting 
reads for this SV. 
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Finally, several other programs (Gustaf, FACTERA, Breakmer, SVdetect), some of 
which are being developed right now, seem to find real breakpoints from soft-clipped 
read ends. Even though having a large list of SVs, it would be possible to follow further 
analysis without spending so much time trying to elucidate their breakpoints. However, 
these softwares are not working properly yet for whole exome sequencing analysis. 
They are working fine for particular genome data (i.e. type of tumor data) and for longer 
reads (100bp or more). Also, their algorithms are really good at finding SVs in a very 
limited size of sequences (GUSTAF). 
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6. Conclusions 
 
It has been performed a pipeline analysis to get a high probability list of 22 SVs from a 
set of whole exome sequencing samples. Once set up, this method could be used in the 
future to perform similar analysis with lots of samples and finally get quick results. 
 
20 out of 22 SVs have been considered true positives, 8 of which are gene fusions. 
Although none of them are recurrent chromosomal rearrangements, it should be 
necessary to validate experimentally these results and further analyze whether these 
gene fusions are able to generate protein products or not.  
 
MTSS1-CCAT1 could be an interesting gene fusion to be studied in the future due to 
their properties, the novel structure and regulation it has taken after the fusion and their 
expression in colorectal cancer. 
 
It has also been hypothesized that gene fusion DLG2-UNC45B found in CLX samples, 
as well as in TCGA Glioblastoma samples
[40]
 and in metastatic cervical carcinoma 
samples
[41]
, is indeed a false positive generated by Breakdancer due to a high similarity 
with an rRNA gene containing a highly repetitive sequence. This discovery highlights 
the necessity of align samples against all the chromosomes sequences (including 
random and unmapped sequences) every time an Structural Variant finding analysis is 
going to be performed.  
 30 
 
References 
 
1. Jemal A, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. 
 
2.- Newman AM, et al. FACTERA: a practical method for the discovery of genomic 
rearrangements at breakpoint resolution. Bioinformatics. 2014;30(23):3390-3393. 
 
3.- Raphael BJ Chapter 6: Structural Variation and Medical Genomics. PLoS Comput Biol 
2013;8(12): e1002821. 
 
4.- Quinlan AR, Hall IM. Characterizing complex structural variation in germline and somatic 
genomes. Trends Genet. 2012;28:43–53. 
 
5.- Mijuskovic M, et al. A streamlined method for detecting structural variants in cancer 
genomes by short read paired-end sequencing. PLoS One 2012;7(10):e48314. 
 
6. Haggar FA, Boushey RP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, 
and Risk Factors. Clinics in Colon and Rectal Surgery. 2009;22(4):191-197 
 
7. Labianca R. et al. Colorectal cancer: screening. Ann Oncol 2005;16(Suppl 2): ii127–ii132 
 
8.- The Cancer Genome Atlas Network. Comprehensivemolecular characterization of human 
colon and rectal cancer. Nature. 2012;487(7407):330-337 
 
9. Ardini E. et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal 
carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 
2014;8(8):1495-1507. 
 
10. Mitelman F, Johansson B, and Mertens F. The impact of translocations and gene fusions on 
cancer causation. Nat Rev Cancer. 2007;7(4):233-245. 
 
11.- Sanz-Pamplona R, et al. Exome Sequencing Reveals AMER1 as a Frequently Mutated 
Gene in Colorectal Cancer. Clin Cancer Res 2015, doi: 10.1158/1078-0432.CCR-15-0159 
 
12.- http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc 
 
13.- Langmead, B. Salzberg, S. Fast gapped-read alignment with Bowtie2. Nature Methods. 
2012, 9:357-359 
 
14.- Li, H. et al. The sequence alignment/map (SAM) format and SAMtools. Bioinformatics, 
2009;25, 2078-2079. 
 
15.- http://picard.sourceforge.net. 
 
16.- Trappe K, et al. Gustaf: Detecting and correctly classifying SVs in the NGS twilight zone. 
Bioinformatics 2014;30(23):3484-3490. 
 
17.- Chen K, et al. BreakDancer: an algorithm for high-resolution mapping of genomic 
structural variation. Nat Methods 2009;6(9):677-681. 
 
18.- Xian F, et al. BreakDancer – Identification of Genomic Structural Variation from Paired-
End Read Mapping. Curr Protoc Bioinformatics. 2014; doi: 10.1002/0471250953.bi1506s45 
 
 31 
 
19.- R Core Team. R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, 2013, Vienna, Austria. URL http://www.R-project.org/  
 
20.- https://genome.ucsc.edu/  
 
21.- Qinlan, AR. Hall, IM. Bedtools: A flexible suite of utilities for comparing genomic 
features. Bioinformatics 2010;26(6):841-842. 
 
22.- Robinson, JT. et al. Integrative Genomics Viewer. Nature Biotechnology 2011;29:24-26. 
 
23.- Madden T. The BLAST Sequence Analysis Tool. 2002 Oct 9 [Updated 2003 Aug 13]. In: 
McEntyre J, Ostell J, editors. The NCBI Handbook [Internet]. Bethesda (MD): National Center 
for Biotechnology Information (US); 2002-. Chapter 16. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK21097/  
 
24.- Tarttelin, Emma E, et al. Neuropsin (Opn5): a novel opsin identified in mammalian neural 
tissue. FEBS Letters 2003;554(3):410-416. 
 
25.- Araki T, Kusakabe M, Nishida E. A Transmembrane Protein EIG121L Is Required for 
Epidermal Differentiation during Early Embryonic Development. The Journal of Biological 
Chemistry 2011;286(8):6760-6768. 
 
26.- http://www.proteinatlas.org/ENSG00000164659-KIAA1324L/tissue  
 
27.- Wang D. MTSS1 overexpression correlates with poor prognosis in colorectal cancer. J 
Gastrointest Surg 2011 Jul;15(7):1205-1212. 
 
28.- Xiang J-F. et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range 
chromatin interactions at the MYC locus. Cell Research 2014;24:513-531. 
 
29.- Zhenyu Y, et al. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal 
cancer and its clinical significance. Int J Clin Exp Med 2015;8(3):3707-3715. 
 
30.- Ochocki JD, Distefano MD. Prenyltransferase Inhibitors: Treating Human Ailments from 
Cancer to Parasitic Infections. Med Chem Comm. 2013;4(3):476-492. 
 
31.- Wang H. et al. Fank1 interacts with Jab1 and regulates cell apoptosis via the AP-1 pathway. 
Cell Mol Life Sci 2011;68(12):2129-2139. 
 
32.- Sillars-Hardebol AH, et al. BCL2L1 has a functional role in colorectal cancer and its 
protein expression is associated with chromosome 20q gain. J Pathol 2012;226(3):442-450. 
 
33.- Prakash S, Robbin PW. Cloning and analysis of the cDNA for human fibrosin, a novel 
fibrogenic lymphokine. DNA Cell Biol 1998;17(10):879-884. 
 
34.- Turner J, Crossley M. Mammalian Kruppel-like transcription factors: more than just a 
pretty finger. Trends Biochem Sci 1999;24:236–240. 
 
35.- Kubo T. A novel FERM domain including guanine nucleotide exchange factor is involved 
in Rac signaling and regulates neurite remodeling. J Neurosci 2002;22(19):8504-8513. 
 
36.- Watterson DM, et al. Analysis of the kinase-related protein gene found at human 
chromosome 3q21 in a multi-gene cluster: organization, expression, alternative splicing, and 
polymorphic marker. J Cell Biochem 1999;75(3):481-491. 
 
 32 
 
37.- Fu J. et al. Ubiquitin ligase cullin 7 induces epithelial-mesenchymal transition in human 
choriocarcinoma cells. J Biol Chem 2010;285(14):10870-10879. 
 
38.- Shin WS, et al. Soluble PTK7 inhibits tube formation, migration, and invasion of 
endothelial cells and angiogenesis. Biochem Biophys Res Commun 2008;371(4):793-798. 
 
39.- Bartoloni L. et al. Axonemal beta heavy chain dynein DNAH9: cDNA sequence, genomic 
structure, and investigation of its role in primary ciliary dyskinesia. Genomics 2001;72(1):21-
33. 
 
40.- Cameron W. Brennan, et al. The Somatic Genomic Landscape of Glioblastoma. Cell 
2013;155:462-477. 
 
41.- Winnie S. Liang, et al. Simultaneous Characterization of Somatic Events and HPV-18 
Integration in a Metastatic Cervical Carcinoma Patient Using DNA and RNA Sequencing. Int J 
Gynecol Cancer 2014; DOI: 10.1097/IGC.0000000000000049 
 33 
 
Appendices 
 
A1. Breakdancer quality controls 
 
 
Supplementary Table 1.  
Coefficient of Variation. 
 
 Normal Sample Tumoral Sample 
A2027 0.316 0.292 
A2050 0.295 0.306 
B2035 0.289 0.293 
B2058 0.306 0.286 
B2081 0.292 0.284 
C2067 0.309 0.298 
D2079 0.283 0.305 
E2023 0.285 0.323 
E2046 0.283 0.283 
E2069 0.293 0.300 
F2008 0.298 0.291 
F2077 0.300 0.274 
H2019 0.325 0.300 
H2042 0.284 0.302 
H2065 0.292 0.306 
J2014 0.291 0.292 
J2037 0.286 0.287 
K2068 0.317 0.285 
L2020 0.281 0.283 
L2089 0.293 0.293 
M2052 0.292 0.314 
N2013 0.294 0.297 
N2036 0.283 0.294 
P2009 0.284 0.311 
P2032 0.285 0.314 
P2078 0.319 0.296 
Q2040 0.287 0.295 
R2002 0.275 0.302 
R2025 0.279 0.298 
R2048 0.289 0.291 
S2016 0.296 0.316 
S2062 0.325 0.319 
T2047 0.304 0.308 
T2093 0.279 0.290 
V2041 0.279 0.286 
W2026 0.303 0.285 
X2034 0.290 0.306 
X2057 0.284 0.291 
X2080 0.311 0.297 
Y2076 0.281 0.286 
Z2038 0.321 0.307 
Z2084 0.299 0.316 
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Supplementary Table 2.  
Percentage of Intrachromosomal reads pairs. 
 
 
Normal 
Sample 
Tumoral 
Sample 
A2027 7.60% 11.52% 
A2050 5.69% 1.62% 
B2035 7.04% 11.00% 
B2058 8.44% 11.44% 
B2081 0.95% 2.04% 
C2067 1.32% 1.65% 
D2079 8.03% 7.11% 
E2023 2.16% 3.52% 
E2046 7.61% 8.51% 
E2069 1.03% 1.24% 
F2008 0.98% 9.70% 
F2077 1.56% 2.58% 
H2019 6.51% 10.40% 
H2042 2.16% 16.86% 
H2065 0.87% 3.56% 
J2014 6.63% 10.68% 
J2037 0.77% 1.04% 
K2068 11.26% 10.02% 
L2020 9.12% 1.73% 
L2089 4.91% 4.00% 
M2052 3.18% 2.41% 
N2013 0.59% 6.78% 
N2036 1.61% 8.14% 
P2009 7.92% 13.39% 
P2032 0.97% 1.37% 
P2078 6.55% 7.47% 
Q2040 12.85% 8.83% 
R2002 6.07% 6.33% 
R2025 5.50% 0.97% 
R2048 1.31% 1.04% 
S2016 7.84% 14.70% 
S2062 2.07% 2.94% 
T2047 7.37% 1.85% 
T2093 6.52% 6.80% 
V2041 6.10% 3.09% 
W2026 9.28% 7.65% 
X2034 1.73% 12.45% 
X2057 5.86% 1.09% 
X2080 10.04% 14.35% 
Y2076 1.23% 2.19% 
Z2038 7.81% 7.99% 
Z2084 2.96% 2.42% 
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Supplementary Figure 1. Insert size distribution histograms for the five first pair of samples 
(A2027 to B2081), the others are very similar. Column 1: Normal Samples, column 2: 
Tumor Samples 
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A2. Integrative Genomic Viewer supplementary alignments 
 
 
Supplementary Figure 2. Discordant reads surrounding SV detected in sample T2093 aligned 
against DLG2-UNC45B gene fusion chimera construct. Mismatches are represented as colored 
vertical lines. 
 
 
Supplementary Figure 3. Discordant reads surrounding SV detected in sample Q2040 aligned 
against DLG2-UNC45B gene fusion chimera construct. Mismatches are represented as colored 
vertical lines. 
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Supplementary Figure 4. Reads surrounding SV detected in sample T2093 aligned against 
chrUn_gl0000220. 
 
 
Supplementary Figure 5. Reads surrounding SV detected in sample Q2040 aligned against 
chrUn_gl0000220. 
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A3. BLAST report for short chimeric sequence carrying DLG2-UNC45B gene fusion 
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Descriptions 
  Sequences producing significant alignments: 
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A4. Scripts used for the analysis 
 
 
1. Breakdancer filtering R. 
 
setwd("/home/46962313Q/extra/align/breakdancer/prova") 
 
# loading interchromosomal table 
sv<- read.table("colonomics_CTX2", sep="\t") 
 
# loading intrachromosomal table 
sv2<- read.table("colonomics_full_bd", sep="\t") 
col<- c("Chr1", "Pos1", "Orientation1", "Chr2", "Pos2", "Orientation2", "Type", "Size", 
"Score", "num_Reads", "num_Reads_lib") 
colnames(sv)<- col 
colnames(sv2)<- col 
 
sv$Chr1<- as.character(sv$Chr1) 
sv$Chr2<- as.character(sv$Chr2) 
sv$num_Reads_lib<- as.character(sv$num_Reads_lib) 
sv$num_Reads_lib<- gsub("/home/46962313Q/extra/align//", " ", sv$num_Reads_lib) 
 
sv2$Chr1<- as.character(sv2$Chr1) 
sv2$Chr2<- as.character(sv2$Chr2) 
sv2$num_Reads_lib<- as.character(sv2$num_Reads_lib) 
sv2$num_Reads_lib<- gsub("/home/46962313Q/extra/align//", " ", 
sv2$num_Reads_lib) 
 
sv_sorted<- sv[order(sv$Chr1, sv$Pos1, sv$Chr2, sv$Pos2),] 
sv_filt<- data.frame(sv_sorted[1,]) 
 
# detecting common CTX in different samples 
i=1 
while (i <(nrow(sv_sorted))) { 
  for (j in i+1:nrow(sv_sorted)) { 
    sv_filt<- rbind(sv_filt, sv_sorted[j,]) 
    if (sv_sorted$Chr1[i] == sv_sorted$Chr1[j] & sv_sorted$Chr2[i] == 
sv_sorted$Chr2[j] & sv_sorted$Pos1[i]-100 < sv_sorted$Pos1[j] & 
sv_sorted$Pos1[i]+100 > sv_sorted$Pos1[j] & sv_sorted$Pos2[i]-100 < 
sv_sorted$Pos2[j] & sv_sorted$Pos2[i]+100 > sv_sorted$Pos2[j]) { 
      sv_filt[i,10]<- sv_filt[i,10] + sv_sorted[j,10] 
      sv_filt[i,11]<- paste(sv_filt[i,11], sv_sorted[j,11], sep=" ") 
      sv_filt[j,11]<- paste(sv_filt[j,11], "duplicated", sep=" ") 
      } else { 
        i<- j 
        break 
    } 
  } 
} 
 
# subset for removing duplicated CTX 
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sv_filt<- subset(sv_filt, !grepl("*duplicated", sv_filt$num_Reads_lib)) 
 
# merging both Breakdancer outputs 
sv_full<- rbind(sv2, sv_filt) 
 
# applying filtering criteria 
select<- c("INV", "CTX", "ITX") 
sv_balanced<- sv_full[sv_full$Type %in% select,] 
# dim(sv_balanced) 
sv_highsup<- subset(sv_balanced, num_Reads>4) 
# dim(sv_highsup) 
sv_somatic<- subset(sv_highsup, !grepl("*_N", sv_highsup$num_Reads_lib)) 
# dim(sv_somatic) 
sv_final<- sv_somatic[c(-1, -3, -4, -5, -9, -10, -12, -13, -15, -16, -18, -19, -20, -21, -22, -
23, -24, -25, -26, -27, -29, -32, -35),] 
# dim(sv_somatic) 
 
# final filtered output 
write.table(sv_final, "sv_candidates.txt", sep="\t", quote=FALSE, col.names=TRUE) 
 
annot1<- data.frame(sv_final$Chr1, sv_final$Pos1, sv_final$Pos1+1) 
colnames(annot1)<- c("Chr", "Pos_s", "Pos_e") 
annot2<- data.frame(sv_final$Chr2, sv_final$Pos2, sv_final$Pos2+1) 
colnames(annot2)<- c("Chr", "Pos_s", "Pos_e") 
annot<- as.data.frame(rbind(annot1, annot2)) 
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2. Alignment pipeline for Illumina paired-end reads. 
 
#!/bin/bash 
#$ -cwd 
#$ -o ./ 
#$ -j y 
#$ -S /bin/bash 
 
EXOMES="/home/46962313Q/exomes/fastq_clx/" 
ALIGN="/home/46962313Q/chromosomes/" 
PICARD="/share/apps/java/jre1.6.0_21/bin/java -jar /share/apps/picard/picard.jar" 
PERL="/share/apps/Perl/bin/perl" 
HG19="/home/46962313Q/reference/bowtie/UCSC_hg19b/hg19" 
BOWTIE2="/share/apps/bowtie2/bowtie2" 
SAMTOOLS="/share/apps/samtools/samtools" 
BREAK="/home/46962313Q/breakdancer/perl/bam2cfg.pl" 
DANCER="/home/46962313Q/breakdancer/build/bin/breakdancer-max" 
PATH=$PATH:/home/46962313Q/bin:/share/apps/Perl/bin 
 
# Tumoral samples only 
cd $EXOMES 
 
samples=`ls *T_1.fastq*` 
samples=${samples//_1.fastq/}  
 
CORES=$((`grep -c ^processor /proc/cpuinfo` -1)) 
 
# test 
#samples=(${samples})  
#samples=${samples[0]}  
echo $samples 
 
cd $ALIGN 
 
for i in $samples 
do 
 
# Bowtie2 local alignment / very sensitive 
$BOWTIE2 --very-sensitive-local -p $CORES -x $HG19 -1 $EXOMES/${i}_1.fastq -2 
$EXOMES/${i}_2.fastq | $SAMTOOLS view -uS - | $SAMTOOLS sort -m 1000000000 - 
$ALIGN/${i} 
 
# Picardtools MarkDuplicates for taggin duplicated reads 
$PICARD MarkDuplicates INPUT=$ALIGN/${i}.bam OUTPUT=$ALIGN/${i}_dup.bam 
METRICS_FILE=$ALIGN/${i}.txt 
 
# Removal of duplicated and or unmapped reads 
$SAMTOOLS view -u -h -F1036 $ALIGN/${i}_dup.bam > $ALIGN/${i}_fil.bam 
 
# Addition of Read Groups 
$PICARD AddOrReplaceReadGroups I=$ALIGN/${i}_fil.bam O=$ALIGN/${i}_RG.bam 
ID=$ALIGN/${i} SM=1 LB=$ALIGN/${i} PL=illumina PU=1 
 
# Index Bam file 
$SAMTOOLS index $ALIGN/${i}_RG.bam 
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done 
 
# Normal samples this time 
cd $EXOMES 
 
samples=`ls *N_1.fastq*` 
samples=${samples//_1.fastq/}  
 
CORES=$((`grep -c ^processor /proc/cpuinfo` -1)) 
 
echo $samples 
 
cd $ALIGN 
 
for i in $samples 
do 
 
# Bowtie2 local alignment / very sensitive 
$BOWTIE2 --very-sensitive-local -p $CORES -x $HG19 -1 $EXOMES/${i}_1.fastq -2 
$EXOMES/${i}_2.fastq | $SAMTOOLS view -uS - | $SAMTOOLS sort -m 1000000000 - 
$ALIGN/${i} 
 
# Picardtools MarkDuplicates for taggin duplicated reads 
$PICARD MarkDuplicates INPUT=$ALIGN/${i}.bam OUTPUT=$ALIGN/${i}_dup.bam 
METRICS_FILE=$ALIGN/${i}.txt 
 
# Removal of duplicated and or unmapped reads 
$SAMTOOLS view -u -h -F1036 $ALIGN/${i}_dup.bam > $ALIGN/${i}_fil.bam 
 
# Addition of Read Groups 
$PICARD AddOrReplaceReadGroups I=$ALIGN/${i}_fil.bam O=$ALIGN/${i}_RG.bam 
ID=$ALIGN/${i} SM=1 LB=$ALIGN/${i} PL=illumina PU=1 
 
# Index Bam file 
$SAMTOOLS index $ALIGN/${i}_RG.bam 
 
done 
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3. Breakdancer script 
 
#!/bin/bash 
#$ -cwd 
#$ -o ./ 
#$ -j y 
#$ -S /bin/bash 
 
ALIGN="/home/46962313Q/extra/align/" 
BREAK="/home/46962313Q/breakdancer/perl/bam2cfg.pl" 
DANCER="/home/46962313Q/breakdancer/build/bin/breakdancer-max" 
PERL="/share/apps/Perl/bin/perl" 
PATH=$PATH:/home/46962313Q/bin:/share/apps/Perl/bin 
 
cd $ALIGN 
 
CORES=$((`grep -c ^processor /proc/cpuinfo` -1)) 
 
# SV calling for interchromosomal events 
samples=`ls *T_RG.bam*` 
samples=${samples//T_RG.bam/} 
 
for i in $samples 
do 
 
$BREAK -g -h ${i}T_RG.bam ${i}N_RG.bam > config_${i} 
$DANCER -t -a config_${i} > col_CTX_${i} 
 
done 
 
 
# SV calling for intrachromosomal events 
$BREAK -g -h `ls *RG.bam` > colonomics_config 
 
$DANCER -o chrX -a colonomics_config > col_chrX_bd 
$DANCER -o chrY -a colonomics_config > col_chrY_bd 
 
for i in {1..22} 
do 
 
$DANCER -o chr${i} -a colonomics_config > col_${i}_bd 
 
done 
 
 
 
